Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin signs marketing alliance with Ascend
Under the terms of the alliance, Ascend Therapeutics will initiate promotion of the product in the US in June 2008. Ascend has a 50-person women’s health sales force
Under the terms of the alliance, Ascend Therapeutics will initiate promotion of the product in the US in June 2008. Ascend has a 50-person women’s health sales force
New England Research Institutes (NERI) said that its assessment of the outcomes in the treatment of abdominal aortic aneurysms demonstrated that the Talent abdominal stent graft’s primary safety
The multi-country, randomized, double-blind, controlled trial will enroll up to 200 breast cancer patients receiving four cycles of myelosuppressive CTX chemotherapy (doxorubicin 60mg/m2/docetaxel 75mg/m2). The study will compare
The agreement includes at least $87 million in product development and sales milestone payments to Emisphere, of which $10 million will be the minimum first year payment, as
Ovation will obtain the exclusive license to the US rights to the product and will own certain assets, including the biologics license application, following approval. The agreement calls
Under the terms of the agreement, iCAD will pay $2 million in cash and $3 million in shares of iCAD common stock. The number of shares issued will
LOR-2040 is currently in an advanced Phase II clinical study in patients with relapsed or refractory acute myeloid leukemia. To provide an adequate supply of LOR-2040 for ongoing
The trial is being conducted in the US, India and Poland. Data collection will be finalized following completion of treatment of the last patients, expected near the end
Taro had received tentative approval for this abbreviated new drug application in October 2007. The company plans to market the product through its US affiliate, Taro Pharmaceuticals USA.
The ATS AP360 heart valve maximizes hemodynamic performance with a new supra-annular cuff design that facilitates implantation, the company said. In a response to the highly individualized and